DLGAP5 regulates malignancy and lenvatinib sensitivity of hepatocellular carcinoma through AKT/mTOR/NF-κB pathway
DLGAP5 promotes malignancy of HCC and reduces cell lenvatinib sensitivity by positively regulating the AKT/mTOR/NF-κB pathway, indicating that DLGAP5 functions as a potential biomarker for clinical prognosis and lenvatinib treatment in HCC.
Authors
- Hao Zou (ORCID: https://orcid.org/0000-0001-9140-418X)
- Zhenyun Yang (ORCID: https://orcid.org/0000-0001-9526-7741)
- Min Deng (ORCID: https://orcid.org/0000-0002-3232-761X)
- Benyi He (ORCID: https://orcid.org/0000-0003-3590-3288)
- Renguo Guan
- R. Zhao
- Zehao Zheng
- Shaohua Li
- Jie Mei
- Wei Wei
- Wenping Lin
- Rongping Guo
- Yuhao Tang
Institutions
- Sun Yat-sen University (CN)
- The Seventh Affiliated Hospital of Sun Yat-sen University (CN)
- Guangdong Academy of Medical Sciences (CN)
- Sun Yat-sen University Cancer Center (CN)
- Guangdong Provincial People's Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1186/s40001-026-03981-1
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 0.00